Altimmune, Inc. (ALT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist. The company has not generated revenue from product sales to date and relies on equity financing and grants.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $5,000 | $362,000 | $15,000 | $389,000 |
| Net Loss | $(22.8M) | $(20.7M) | $(71.9M) | $(56.8M) |
| Loss Per Share (Diluted) | $(0.32) | $(0.39) | $(1.01) | $(1.10) |
| Operating Expenses | $24.8M | $22.9M | $78.3M | $62.7M |
| Cash & Equivalents | $31.5M (as of Sept 30, 2024) | |||
| Short-Term Investments | ||||
| Total Liquidity | $139.4M (Cash + Investments) | |||
| Accumulated Deficit | $538.2M (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 99% in Q3 and 96% YTD compared to 2023, as the company closed out remaining government grant contracts.
- Increased Operating Loss: Net loss increased 11% in Q3 and 27% YTD. This was driven by higher R&D spending, partially offset by increased interest income ($1.9M in Q3 vs $1.9M in Q3 2023; $6.5M YTD vs $5.4M YTD).
- R&D Spend Shift: R&D expenses rose 8% in Q3 and 28% YTD. The increase is primarily due to the ramp-up of the IMPACT Phase 2b trial for MASH ($5.9M increase in Q3). This was partially offset by the wind-down of the MOMENTUM Phase 2 obesity trial and the discontinuation of the HepTcell program.
- Liquidity Position: Cash and cash equivalents decreased from $135.1M at year-end 2023 to $31.5M at Sept 30, 2024. However, short-term investments increased to $107.9M, resulting in total liquid assets of $139.4M.
Outlook, Risks, and Management Commentary
- Product Pipeline:
- Pemvidutide: Successfully completed End-of-Phase 2 meeting with the FDA. A Phase 3 registrational program for obesity is planned, involving four trials and ~5,000 subjects. Enrollment for the IMPACT Phase 2b MASH trial is complete, with top-line data expected in Q2 2025.
- HepTcell: Development stopped in March 2024 due to insufficient Phase 2 response.
- Liquidity Outlook: Management believes current cash and investments ($139.4M) are sufficient to fund operations for at least 12 months from the filing date. No shares were sold under the At-The-Market (ATM) program in the first nine months of 2024; $60.6M remains available under the ATM shelf.
- Legal Proceedings:
- Class Action: A securities class action lawsuit was filed in May 2024 alleging false/misleading statements between Dec 2023 and April 2024. A second similar complaint was consolidated in October 2024.
- Derivative Action: A shareholder derivative suit was filed in June 2024 against officers and directors, alleging breaches of fiduciary duty. This action was stayed pending the outcome of the Class Action.
- Unusual Items: The company recorded $1.0M in incremental stock-based compensation expense in Q3 due to the modification of awards for the former CFO upon termination.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $139.4M liquidity position against the projected costs of the new Phase 3 obesity program.
- Legal Exposure: Monitor the status of the consolidated securities class action and derivative litigation for potential settlement costs or management distraction.
- ATM Availability: Confirm the remaining $60.6M capacity under the At-The-Market offering agreement as a potential source of future dilution.
- Clinical Milestones: Track the Q2 2025 data readout for the IMPACT MASH trial and the initiation timeline for the Phase 3 obesity trials.
- Expense Management: Assess if the wind-down of HepTcell and MOMENTUM trials will sufficiently offset the ramp-up costs of IMPACT and Phase 3 preparations to stabilize the burn rate.